US2008003620A1PendingUtilityA1

Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinase

Assignee: RIGEL PHARMACEUTICALS INCPriority: Jul 16, 2002Filed: Dec 8, 2006Published: Jan 3, 2008
Est. expiryJul 16, 2022(expired)· nominal 20-yr term from priority
A61K 31/00C12N 9/1205A61K 31/7076
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

Claims

exact text as granted — not AI-modified
1 . A method of identifying a compound that modulates IL4 receptor-mediated IgE production or a process associated therewith, comprising determining whether the compound binds An adenosine kinase, wherein the ability to bind the adenosine kinase identifies the compound as being a modulator of IL-4 induced IgE production or a process associated therewith.  
     
     
         2 - 52 . (canceled)

Join the waitlist — get patent alerts

Track US2008003620A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.